S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

Vivos Stock Forecast, Price & News

-0.01 (-3.85 %)
(As of 01/15/2021 12:00 AM ET)
Today's Range
Now: $0.25
50-Day Range
MA: $0.11
52-Week Range
Now: $0.25
Volume9.71 million shs
Average Volume6.39 million shs
Market Capitalization$72.55 million
P/E RatioN/A
Dividend YieldN/A
Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 is headquartered in Richland, Washington.


Overall MarketRank

0.17 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolOTCMKTS:RDGL
Phone509 736 4000



Sales & Book Value

Annual Sales$10,000.00
Book Value($0.06) per share


Net Income$-1,610,000.00


Market Cap$72.55 million
Next Earnings DateN/A
OptionableNot Optionable
-0.01 (-3.85 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RDGL News and Ratings via Email

Sign-up to receive the latest news and ratings for RDGL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Vivos (OTCMKTS:RDGL) Frequently Asked Questions

How has Vivos' stock price been impacted by Coronavirus?

Vivos' stock was trading at $0.0298 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RDGL stock has increased by 738.9% and is now trading at $0.25.
View which stocks have been most impacted by COVID-19

What stocks does MarketBeat like better than Vivos?

Wall Street analysts have given Vivos a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Vivos wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Vivos' key competitors?

Who are Vivos' key executives?

Vivos' management team includes the following people:
  • Dr. Michael K. Korenko, CEO, Pres & Director (Age 75, Pay $120k)
  • Dr. Carlton M. Cadwell, Independent Chairman & Sec. (Age 76)
  • Mr. Michael H. Pollack CPA, CPA, Chief Financial Officer (Age 55)
  • Dr. David J. Swanberg M.S., P.E., Chief Technical Mang. (Age 64)
  • Dr. Nigel R. Stevenson, Chief Science Officer
  • Dr. Fu-Min Su, Chief Radio Chemist & Radiation Safety Officer

What is Vivos' stock symbol?

Vivos trades on the OTCMKTS under the ticker symbol "RDGL."

How do I buy shares of Vivos?

Shares of RDGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vivos' stock price today?

One share of RDGL stock can currently be purchased for approximately $0.25.

How big of a company is Vivos?

Vivos has a market capitalization of $72.55 million and generates $10,000.00 in revenue each year. Vivos employs 1 workers across the globe.

What is Vivos' official website?

The official website for Vivos is www.radiogel.com.

How can I contact Vivos?

Vivos' mailing address is 719 JADWIN AVENUE, RICHLAND WA, 99352. The company can be reached via phone at 509 736 4000.

This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.